Parkinson’s Disease Treatment Market Projected to Reach $8.75 Billion by 2032 as Advancements in Drug Therapy and Brain Stimulation Drive New Standards of Care – SNS Insider

Market Overview - The global Parkinson's Disease Treatment Market was valued at $5.37 billion in 2023 and is projected to reach $8.75 billion by 2032, reflecting a CAGR of 5.57% from 2024 to 2032 [1][18]. - Parkinson's disease is one of the fastest-growing neurological disorders, with a rising prevalence accelerating demand for effective therapies [5]. Treatment Landscape - Traditional medications like levodopa remain primary treatment options, with approximately 1 million individuals in the U.S. relying on it, and nearly 70% of patients receiving it at some point [5]. - Advanced interventions such as deep brain stimulation (DBS) are becoming more accessible, with over 25,000 procedures performed in the U.S. in 2023 [6]. - High therapy costs and the chronic nature of the disease are challenges, but ongoing research and expanded coverage options are improving long-term patient outcomes [7]. Market Segmentation - By Drug Class: Carbidopa-levodopa held over 30% market share in 2023, while dopamine agonists are experiencing the fastest growth rate [9]. - By Sales Channel: The retail sector accounted for 61% of the market share in 2023, with hospitals expected to have a faster CAGR during 2024-2032 [10]. Regional Insights - North America dominated the market in 2023 with a 39% share, attributed to advanced healthcare facilities and significant R&D investments [11]. - The Asia Pacific region is expected to experience the most rapid growth during the forecast period due to increased healthcare spending and awareness of neurological conditions [12]. Key Companies - Major companies in the Parkinson's treatment market include AbbVie, Johnson and Johnson, Novartis, and Teva Pharmaceutical Industries [8].